Ergomed plc Director's Dealing (6627W)
19 Abril 2023 - 1:00AM
UK Regulatory
TIDMERGO
RNS Number : 6627W
Ergomed plc
19 April 2023
Director's Dealing
Guildford, UK - 19 April 2023 : Ergomed plc (LSE: ERGO)
("Ergomed" or the "Company"), a company focused on providing
specialised services to the pharmaceutical industry, announces that
on 19 April 2023, Dr Miroslav Reljanović, Executive Chairman of
Ergomed, transferred 400,000 ordinary shares of 1p each in the
Company ("Ordinary Shares") to a former director of the Company.
The transfer took place following an exercise of options under an
option agreement dated 5 August 2019 between Dr Reljanović and the
former director and the exercise price was 1p per ordinary
share.
Following the transfer, Dr Reljanović holds 9,129,297 ordinary
shares representing 17.98% of the Company's issued share
capital.
The relevant notifications set out below are provided in
accordance with the requirements of Article 19 of the UK Market
Abuse Regulation.
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Dr Miroslav Reljanović
-------------------------------------- -----------------------------------
2 Reason for the notification
---------------------------------------------------------------------------
a) Position/status Executive Chairman
-------------------------------------- -----------------------------------
b) Initial notification Initial Notification
/Amendment
-------------------------------------- -----------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------------
a) Name Ergomed plc
-------------------------------------- -----------------------------------
b) Legal Entity 213800BVS8I9VMC1AP84
Identifier
-------------------------------------- -----------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
---------------------------------------------------------------------------
a) Description Ordinary shares of 1 pence each
of the financial
instrument,
type of instrument GB00BN7ZCY67
Identification
code
-------------------------------------- -----------------------------------
b) Nature of the Transfer of shares
transaction
-------------------------------------- -----------------------------------
c) Currency GBP
-------------------------------------- -----------------------------------
d) Price(s) and Price(s) Volume(s)
volume(s)
-------------------------------------- ---------------- -----------------
GBP0.01 400,000
------------------------------------------------------------ -----------------
e) Aggregated
information
400,000
- Aggregated
volume GBP0.01
- Price GBP4,000
- Aggregated
total
-------------------------------------- -----------------------------------
f) Date of the 19 April 2023
transaction
-------------------------------------- -----------------------------------
g) Place of the London Stock Exchange, AIM
transaction
-------------------------------------- -----------------------------------
ENDS
Enquiries:
Ergomed plc Tel: +44 (0) 1483 402
975
Miroslav Reljanović (Executive
Chairman)
Jonathan Curtain (Chief Financial Officer)
Keith Byrne (Senior Vice President,
Capital Markets and Strategy)
Numis Securities Limited (Nominated Tel: +44 (0) 20 7260
Adviser and Joint Broker) 1000
Freddie Barnfield / Euan Brown / Jack
McLaren
Peel Hunt Securities Limited (Joint
Broker) Tel: +44 (0) 20 7418
James Steel / Dr Christopher Golden 8900
Consilium Strategic Communications Tel: +44 (0) 20 3709
- for UK enquiries 5700
Chris Gardner / Matthew Neal ergomed@consilium-comms.com
About Ergomed plc
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical
industry spanning all phases of clinical development, post-approval
pharmacovigilance and medical information. Ergomed's fast-growing
services business includes an industry-leading suite of specialist
pharmacovigilance (PV) solutions, integrated under the
PrimeVigilance brand, a full range of high-quality clinical
research and trial management services under the Ergomed brand
(CRO) and mission-critical regulatory compliance and consulting
services under the ADAMAS brand. For further information, visit:
http://ergomedplc.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHEAPLPFFFDEFA
(END) Dow Jones Newswires
April 19, 2023 02:00 ET (06:00 GMT)
Ergomed (LSE:ERGO)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Ergomed (LSE:ERGO)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
